logo-loader

Life Sciences company Quanterix launches IPO at US$14 to US$16 per share

Last updated: 08:06 27 Nov 2017 EST, First published: 03:06 27 Nov 2017 EST

test tubes
Its technology is currently being used for research applications in oncology, neurology, cardiology, inflammation and infectious disease.

Quanterix Corp (NASDAQ:OTRX) has launched its Initial Public Offering (IPO) on Monday, offering a total of 3.34 million shares priced at US$14 to US$16 per share.

At the midpoint price range, the company will raise a total of US$50.1mln.

Company digitises biomarker analysis

J.P. Morgan, Leerink Partners and Cowen are joint bookrunners on the deal with BTIG and Evercore ISI acting as co-managers. The life sciences company is set to list on Nasdaq.

The Massachusetts-based company will use the proceeds from the IPO to expand its commercial operations, improve and update its Simoa technology, as well as support a 2018 product launch.

Part of the monies will also go towards moving to a larger corporate headquarters, seek regulatory approval to develop certain instruments, to pursue acquisitions and for general corporate purposes.

Quanterix digitises biomarker analysis with the aim of advancing the science of precision health. Its technology is aimed at enabling earlier detection of disease, better prognosis and enhanced treatment methods to improve the quality and longevity of life.

Its technology is currently being used for research applications in oncology, neurology, cardiology, inflammation and infectious disease.

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

8 hours, 45 minutes ago